Non-immunogenic staphylokinase in the treatment of high-risk massive pulmonary embolism in the early postoperative period due to femoral fragment wound
A case report of double thrombolytic therapy with non-immunogenic staphylokinase at a dose of 15 mg bolus over 15 s in a patient with a high-risk massive pulmonary embolism (PE) in the early postoperative period due to femoral wound is described. After the second thrombolysis, a decrease in the pulm...
Saved in:
| Main Authors: | S. L. Konstantinov, G. I. Stryabkova, A. I. Basarab, V. N. Kravchuk, I. V. Kаzhanov, S. V. Ivanov, Zh. Yu. Chefranova, S. S. Markin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2023-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2957 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Non-immunogenic staphylokinase in the high-risk pulmonary embolism treatment with subdural hematoma
by: S. L. Konstantinov, et al.
Published: (2025-08-01) -
Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial
by: A. I. Kirienko, et al.
Published: (2024-12-01) -
Assessment of the allergenic and immunotoxic properties of the recombinant non-immunogenic staphylokinase in preclinical and clinical trials
by: S. S. Markin, et al.
Published: (2025-07-01) -
Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial
by: S. N. Tereshchenko, et al.
Published: (2025-03-01) -
The Safety of Non‐immunogenic Recombinant Staphylokinase in Elderly Patients With Massive Pulmonary Embolism: A Randomized Clinical Trial FORPE
by: Stanislav G. Leontyev, et al.
Published: (2025-05-01)